Earnings ·
SELLAS Life Sciences Group, Inc. reported financial results for the quarter ended June 30, 2026, showing a net loss of…
SLSSELLAS Life Sciences Group, Inc.
SELLAS Life Sciences Group, Inc. reported financial results for the quarter ended June 30, 2026, showing a net loss of $9.6 million, or $0.05 per share, compared to a $6.6 million loss in the prior year period. Research and development expenses increased to $6.3 million from $3.9 million, while general and administrative expenses rose to $4.4 million from $3.0 million. The company held $138.3 million in cash as of June 30, 2026. Clinically, the Phase 3 REGAL trial for galinpepimut-S (GPS) is approaching the pre-specified 80th event required for final efficacy analysis, while enrollment continues in the Phase 2 SLS009 study with topline data expected in Q4 2026. The company operates in the biopharmaceutical industry, developing novel cancer therapies.